These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9754843)

  • 1. Methodological issues of human experimental research with hallucinogens.
    Gouzoulis-Mayfrank E; Schneider F; Friedrich J; Spitzer M; Thelen B; Sass H
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():114-8. PubMed ID: 9754843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin research: contributions to understanding psychoses.
    Geyer MA; Vollenweider FX
    Trends Pharmacol Sci; 2008 Sep; 29(9):445-53. PubMed ID: 19086254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
    Gouzoulis-Mayfrank E; Schreckenberger M; Sabri O; Arning C; Thelen B; Spitzer M; Kovar KA; Hermle L; Büll U; Sass H
    Neuropsychopharmacology; 1999 Jun; 20(6):565-81. PubMed ID: 10327426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
    Gouzoulis-Mayfrank E; Thelen B; Maier S; Heekeren K; Kovar KA; Sass H; Spitzer M
    Neuropsychobiology; 2002; 45(4):205-12. PubMed ID: 12097810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
    Vollenweider FX
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():92-103. PubMed ID: 9754840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.
    Gouzoulis-Mayfrank E; Thelen B; Habermeyer E; Kunert HJ; Kovar KA; Lindenblatt H; Hermle L; Spitzer M; Sass H
    Psychopharmacology (Berl); 1999 Feb; 142(1):41-50. PubMed ID: 10102781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expressive phenomenology of model psychoses (psilocybin). Comparison with self-description and psychic deficiency of performance].
    HEIMANN H
    Psychiatr Neurol (Basel); 1961 Jan; 141():69-100. PubMed ID: 13712866
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serotonin metabolism in experimental psilocybin psychosis].
    VITEK V; VOJTECHOVSKY M; GROF S
    Act Nerv Super (Praha); 1961 May; 3():213-5. PubMed ID: 13926289
    [No Abstract]   [Full Text] [Related]  

  • 10. Peak experiences of psilocybin users and non-users.
    Cummins C; Lyke J
    J Psychoactive Drugs; 2013; 45(2):189-94. PubMed ID: 23909006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human hallucinogen interactions with drugs affecting serotonergic neurotransmission.
    Strassman RJ
    Neuropsychopharmacology; 1992 Nov; 7(3):241-3. PubMed ID: 1388647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human hallucinogenic drug research: regulatory, clinical, and scientific issues.
    Strassman RJ
    NIDA Res Monogr; 1994; 146():92-123. PubMed ID: 8742796
    [No Abstract]   [Full Text] [Related]  

  • 14. Discriminative stimulus properties of hallucinogens and related designer drugs.
    Glennon RA
    NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hermeneutic psychopathology of psychoses: scientific basis, concepts, and clinical aspects].
    Schmidt-Degenhard M; Feldmann H
    Nervenarzt; 2003 Jan; 74(1):16-22. PubMed ID: 12596023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive changes in behavior after repeated administration of various psychoactive drugs.
    Rech RH; Tilson HA; Marquis WJ
    Adv Biochem Psychopharmacol; 1975; 13():263-86. PubMed ID: 1163377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry.
    Gouzoulis-Mayfrank E; Hermle L; Thelen B; Sass H
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():63-8. PubMed ID: 9754835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.
    Dittrich A
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():80-4. PubMed ID: 9754838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hallucinogenic botanicals of America: a growing need for focused drug education and research.
    Halpern JH; Sewell RA
    Life Sci; 2005 Dec; 78(5):519-26. PubMed ID: 16188280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.